UNSPSC 51383003: Tomoxiprole

This classification denotes a cyclooxygenase inhibitor with the molecular formula C21H20N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EZ948T2878, chemically known as 3-isopropyl-2-(p-methoxyphenyl)-3h-naphth(1,2-d)imidazole but generally known as tomoxiprole, which bears US NIH Compound Identifier 53454. European Medicines Agency schedules Tomoxiprole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11187MIG.

UNSPSC 51383003 Tomoxiprole, a Commodity-tier code, does not align with the recent state and local procurement activity tagged under it. The three recent opportunities reflect purchases of naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and a market-intelligence RFI on direct-to-manufacturer prescription programs — none of which match the specific pharmaceutical product (tomoxiprole) that the code nominally describes. The issuing bodies include county health departments, state health agencies, and multistate cooperative purchasing alliances, but the actual goods being procured fall outside the tomoxiprole category.

Recent activity appears across Florida, Minnesota, Oregon (through cooperative purchasing), and Texas, though the sample is too small to signal sustained market demand under this specific code. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP for generic multi-source pharmaceuticals and OTC products on January 20, 2026, due March 26, 2026, with awards effective July 1, 2026; and the Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs. The mismatch between the code's nominal scope and the opportunities actually tagged suggests either a cataloging error or that tomoxiprole procurement does not generate measurable state and local activity currently.